A 52-year-old man from Mumbai presents with a 3-month history of progressive jaundice, pale stools, and dark urine. On examination, he has hepatomegaly and a palpable gallbladder. Abdominal ultrasound shows a 4 cm hypoechoic lesion in the pancreatic head with dilated intrahepatic bile ducts. Serum bilirubin is 8.2 mg/dL (direct 6.8 mg/dL), alkaline phosphatase 320 U/L, and ALT 95 U/L. A tumor marker is ordered. Which of the following tumor markers would be MOST specific and clinically useful for monitoring disease progression and treatment response in pancreatic cancer?

Explanation

## Clinical Context The patient presents with classic features of pancreatic head cancer: obstructive jaundice, pale stools, dark urine, hepatomegaly, and a mass on imaging. The question asks which tumor marker is most specific and useful for monitoring pancreatic cancer. ## CA 19-9: The Gold Standard for Pancreatic Cancer **High-Yield:** CA 19-9 is the most widely used and clinically relevant tumor marker for pancreatic adenocarcinoma. It is a Lewis antigen-related carbohydrate antigen present on the surface of pancreatic cancer cells. ### Sensitivity and Specificity - **Sensitivity:** 80–85% in advanced pancreatic cancer; lower (~50%) in early-stage disease - **Specificity:** ~90% for pancreatic cancer (but can be elevated in benign conditions: pancreatitis, cirrhosis, cholangitis) - **Prognostic value:** Baseline CA 19-9 >1000 U/mL indicates advanced/metastatic disease ### Clinical Applications | Application | Role | | --- | --- | | **Screening** | Not recommended (low sensitivity in early disease) | | **Diagnosis** | Supportive; not diagnostic alone (requires imaging + histology) | | **Monitoring** | **Most useful**—tracks response to chemotherapy and recurrence | | **Prognosis** | High levels correlate with poor survival | | **Treatment decisions** | Rising CA 19-9 may prompt change in chemotherapy regimen | **Key Point:** A decline in CA 19-9 during chemotherapy correlates with tumor response; persistent elevation or rise suggests treatment failure or progression. ### Normal Range - **< 37 U/mL** is considered normal - In this patient, CA 19-9 would likely be markedly elevated (often >200–1000 U/mL in advanced disease) ## Why CA 19-9 Over Other Markers? **Clinical Pearl:** CA 19-9 is organ-specific (pancreas, biliary tract, stomach) and has become the standard tumor marker for pancreatic cancer surveillance in clinical practice and clinical trials. **Mnemonic:** **PACA** — **P**ancreatic **A**denocarcinoma uses **CA 19-9** for monitoring. ## Limitations - **False positives:** Benign pancreatitis, cholangitis, cirrhosis, gastric ulcer disease can raise CA 19-9 - **Lewis antigen negativity:** ~10% of pancreatic cancer patients are Lewis antigen-negative and will never produce CA 19-9 (cannot be used in these patients) - **Not diagnostic alone:** Always requires imaging and tissue confirmation [cite:Harrison 21e Ch 297]